ULK1 TPD

Txinno Bioscience's ULK1 TPD is a preclinical-stage small molecule designed to selectively induce the degradation of Unc-51 Like Autophagy Activating Kinase 1 (ULK1). ULK1 is a key serine/threonine kinase that initiates the autophagy pathway, a cellular process often hijacked by cancer cells to survive metabolic stress and treatment-induced damage. Unlike traditional inhibitors that only block kinase activity, this targeted protein degrader (TPD) utilizes the cell's ubiquitin-proteasome system to eliminate the ULK1 protein entirely, potentially offering more robust inhibition of autophagy-mediated resistance in various cancers. The program is currently in the preclinical candidate nomination phase and is being developed in collaboration with several South Korean research institutes and pharmaceutical partners.

Other names

ULK1 targeted protein degraderULK-1 targeted protein degraderULK 1 targeted protein degrader